PL3977996T3 - Leczenie zespołu tourette’a - Google Patents
Leczenie zespołu tourette’aInfo
- Publication number
- PL3977996T3 PL3977996T3 PL21201628.1T PL21201628T PL3977996T3 PL 3977996 T3 PL3977996 T3 PL 3977996T3 PL 21201628 T PL21201628 T PL 21201628T PL 3977996 T3 PL3977996 T3 PL 3977996T3
- Authority
- PL
- Poland
- Prior art keywords
- tourette syndrome
- treating tourette
- treating
- syndrome
- tourette
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Photoreceptors In Electrophotography (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562215636P | 2015-09-08 | 2015-09-08 | |
| US201562215673P | 2015-09-08 | 2015-09-08 | |
| US201562215628P | 2015-09-08 | 2015-09-08 | |
| US201562215633P | 2015-09-08 | 2015-09-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3977996T3 true PL3977996T3 (pl) | 2024-07-01 |
Family
ID=56943962
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL22156141.8T PL4023222T3 (pl) | 2015-09-08 | 2016-09-07 | Nieselektywny aktywator metabotropowych receptorów glutaminianu do leczenia zespołu 22q |
| PL21201628.1T PL3977996T3 (pl) | 2015-09-08 | 2016-09-07 | Leczenie zespołu tourette’a |
| PL21201653.9T PL3964213T3 (pl) | 2015-09-08 | 2016-09-07 | Leczenie zaburzeń zachowania |
| PL21170586.8T PL3922249T3 (pl) | 2015-09-08 | 2016-09-07 | Diagnozowanie i leczenie zaburzeń lękowych |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL22156141.8T PL4023222T3 (pl) | 2015-09-08 | 2016-09-07 | Nieselektywny aktywator metabotropowych receptorów glutaminianu do leczenia zespołu 22q |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21201653.9T PL3964213T3 (pl) | 2015-09-08 | 2016-09-07 | Leczenie zaburzeń zachowania |
| PL21170586.8T PL3922249T3 (pl) | 2015-09-08 | 2016-09-07 | Diagnozowanie i leczenie zaburzeń lękowych |
Country Status (12)
| Country | Link |
|---|---|
| US (14) | US20170087139A1 (pl) |
| EP (12) | EP4023222B1 (pl) |
| JP (11) | JP7281280B2 (pl) |
| CN (7) | CN116919961A (pl) |
| AU (10) | AU2016318775B2 (pl) |
| CA (5) | CA2997188C (pl) |
| DK (4) | DK3347015T3 (pl) |
| ES (8) | ES2876898T3 (pl) |
| IL (13) | IL316145A (pl) |
| PL (4) | PL4023222T3 (pl) |
| SG (1) | SG10202012842SA (pl) |
| WO (4) | WO2017044497A1 (pl) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2807505A1 (en) | 2010-08-24 | 2012-03-01 | The Children's Hospital Of Philadelphia | Association of rare recurrent genetic variations to attention-deficit, hyperactivity disorder (adhd) and methods of use thereof for the diagnosis and treatment of the same |
| PL4023222T3 (pl) | 2015-09-08 | 2025-03-24 | The Children's Hospital Of Philadelphia | Nieselektywny aktywator metabotropowych receptorów glutaminianu do leczenia zespołu 22q |
| US20200143922A1 (en) * | 2016-06-03 | 2020-05-07 | Yale University | Methods and apparatus for predicting depression treatment outcomes |
| EP3509640A1 (en) * | 2016-09-07 | 2019-07-17 | The Children's Hospital of Philadelphia | Nonselective metabotropic glutamate receptor activators for treatment of anorexia nervosa and binge eating disorder |
| WO2018195184A1 (en) | 2017-04-19 | 2018-10-25 | Aevi Genomics Medicine, Inc. | Methods of diagnosing and treating adhd in biomarker positive subjects |
| US20200061155A1 (en) * | 2017-05-11 | 2020-02-27 | Ophidion, Inc | Compositions and methods for treating lynx2 disorders |
| CN107483425B (zh) * | 2017-08-08 | 2020-12-18 | 北京盛华安信息技术有限公司 | 基于攻击链的复合攻击检测方法 |
| US11535604B2 (en) | 2018-01-18 | 2022-12-27 | The Children's Hospital Of Philadelphia | Fasoracetam crystalline forms |
| KR102877903B1 (ko) | 2018-01-18 | 2025-10-31 | 더 칠드런스 호스피탈 오브 필라델피아 | 파소라세탐의 고체 형태 |
| KR102250063B1 (ko) * | 2019-06-14 | 2021-05-12 | 한국생명공학연구원 | 뚜렛증후군의 원인 유전자를 동정하는 방법 |
| CN110955751A (zh) * | 2019-11-13 | 2020-04-03 | 广州供电局有限公司 | 工作票文本去重方法、装置、系统及计算机存储介质 |
| WO2022061287A1 (en) * | 2020-09-21 | 2022-03-24 | Reveragen Biopharma, Inc. | TREATMENT OF NF-κB-MEDIATED DISEASE |
| WO2022065518A1 (ja) * | 2020-09-23 | 2022-03-31 | 国立大学法人京都大学 | 神経突起伸長促進剤 |
| KR20240112047A (ko) * | 2023-01-11 | 2024-07-18 | 차의과학대학교 산학협력단 | 불안장애를 진단하기 위한 바이오마커 및 이의 용도 |
| CN117594119B (zh) * | 2024-01-17 | 2024-05-10 | 北京大学第六医院 | 用于预测帕罗西汀或其药用盐对抑郁或焦虑症患者疗效的装置 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995003801A1 (en) * | 1993-07-28 | 1995-02-09 | Nippon Shinyaku Co., Ltd. | Antidepressant |
| WO1999036064A2 (en) * | 1998-01-13 | 1999-07-22 | Synchroneuron, Llc | Methods of treating tardive dyskinesia and other movement disorders |
| US20040116505A1 (en) * | 2001-02-23 | 2004-06-17 | Gregory Krauss | Treatment of tics, tremors and related disorders |
| DE10119330A1 (de) * | 2001-04-19 | 2002-10-24 | Basf Ag | Verfahren zur Herstellung einer wässrigen Polymerdispersion durch radikalische wässrige Emulsionspolymerisation mit einer kontinuierlich hergestellten wässrigen Monomerenemulsion |
| EP1456418A4 (en) | 2001-12-20 | 2006-07-26 | Merck & Co Inc | IDENTIFICATION OF NEW POLYMORPHIC LOCATIONS IN THE HUMAN MGLUR8 GEN AND USES THEREOF |
| WO2005094801A1 (en) | 2004-03-25 | 2005-10-13 | Smithkline Beecham Corporation | Use of an nk3 antagonist for the treatment of bipolar disorders |
| US20100216734A1 (en) * | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| US20070244143A1 (en) | 2006-03-08 | 2007-10-18 | Braincells, Inc | Modulation of neurogenesis by nootropic agents |
| TW200819458A (en) | 2006-06-23 | 2008-05-01 | Merz Pharma Gmbh & Co Kgaa | Metabotropic glutamate receptor modulators |
| WO2008118258A2 (en) | 2007-02-06 | 2008-10-02 | Genizon Biosciences Inc. | Genemap of the human genes associated with adhd |
| WO2008136995A1 (en) | 2007-04-30 | 2008-11-13 | The Ohio State University Research Foundation | Polymorphisms in genes affecting dopamine transporter disorders and uses thereof |
| US20090176740A1 (en) | 2007-11-30 | 2009-07-09 | Phillips Ii Dauglas James | Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine |
| WO2009105718A1 (en) | 2008-02-20 | 2009-08-27 | The Children's Hospital Of Philadelphia | Genetic alterations associated with autism and the autistic phenotype and methods of use thereof for the diagnosis and treatmemt of autism |
| AU2009313759B2 (en) | 2008-11-14 | 2016-05-12 | The Children's Hospital Of Philadelphia | Genetic variants underlying human cognition and methods of use thereof as diagnostic and therapeutic targets |
| WO2010057132A1 (en) | 2008-11-14 | 2010-05-20 | The Children's Hospital Of Philadelphia | Genetic alterations associated with schizophrenia and methods of use thereof for the diagnosis and treatment of the same |
| US8975286B2 (en) | 2009-08-20 | 2015-03-10 | Merck Sharp & Dohme Corp. | Ether benzotriazole derivatives |
| US8714471B2 (en) * | 2010-07-29 | 2014-05-06 | Brady Worldwide, Inc. | Friction core brake |
| CA2807505A1 (en) * | 2010-08-24 | 2012-03-01 | The Children's Hospital Of Philadelphia | Association of rare recurrent genetic variations to attention-deficit, hyperactivity disorder (adhd) and methods of use thereof for the diagnosis and treatment of the same |
| US20130225623A1 (en) | 2010-10-27 | 2013-08-29 | Mount Sinai School Of Medicine | Methods of Treating Psychiatric or Neurological Disorders with MGLUR Antagonists |
| US20140315992A1 (en) | 2011-07-07 | 2014-10-23 | The Children's Hospital Of Philadelphia | Genetic Alterations Associated with Autism and the Autistic Phenotype and Methods of Use Thereof for the Diagnosis and Treatment of Autism |
| US20130143867A1 (en) * | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
| KR20150096370A (ko) * | 2012-08-23 | 2015-08-24 | 스튜어트 엘. 웨그 | 항불안제 조성물, 제형 및 사용방법 |
| US9346239B2 (en) | 2012-09-26 | 2016-05-24 | Eastman Kodak Company | Method for providing patterns of functional materials |
| WO2014152965A2 (en) | 2013-03-14 | 2014-09-25 | The Children's Hospital Of Philadelphia | Schizophrenia-associated genetic loci identified in genome wide association studies and use thereof as novel therapeutic targets |
| US11219617B2 (en) | 2014-05-30 | 2022-01-11 | The Children's Hospital Of Philadelphia | Methods of diagnosing and treating autism |
| SG11201609832XA (en) | 2014-05-30 | 2016-12-29 | Philadelphia Children Hospital | Genetic alterations associated with autism and autistic phenotype and methods of diagnosing and treating autism |
| KR102232583B1 (ko) | 2015-01-08 | 2021-03-26 | 삼성전자주식회사 | 전자장치 및 전자장치의 웹 재현 방법 |
| AU2016278053A1 (en) | 2015-06-15 | 2018-01-04 | The Children's Hospital Of Philadelphia | Methods of diagnosing and treating autism |
| PL4023222T3 (pl) | 2015-09-08 | 2025-03-24 | The Children's Hospital Of Philadelphia | Nieselektywny aktywator metabotropowych receptorów glutaminianu do leczenia zespołu 22q |
-
2016
- 2016-09-07 PL PL22156141.8T patent/PL4023222T3/pl unknown
- 2016-09-07 CN CN202310713811.5A patent/CN116919961A/zh active Pending
- 2016-09-07 CA CA2997188A patent/CA2997188C/en active Active
- 2016-09-07 EP EP22156141.8A patent/EP4023222B1/en active Active
- 2016-09-07 IL IL316145A patent/IL316145A/en unknown
- 2016-09-07 CN CN201680065071.7A patent/CN108601776A/zh active Pending
- 2016-09-07 DK DK16767115.5T patent/DK3347015T3/da active
- 2016-09-07 CN CN202211219188.XA patent/CN115919852A/zh active Pending
- 2016-09-07 EP EP16771034.2A patent/EP3347016B1/en active Active
- 2016-09-07 ES ES16771034T patent/ES2876898T3/es active Active
- 2016-09-07 WO PCT/US2016/050573 patent/WO2017044497A1/en not_active Ceased
- 2016-09-07 ES ES22156141T patent/ES3009523T3/es active Active
- 2016-09-07 CA CA3225374A patent/CA3225374A1/en active Pending
- 2016-09-07 ES ES16767114T patent/ES2897953T3/es active Active
- 2016-09-07 US US15/258,924 patent/US20170087139A1/en not_active Abandoned
- 2016-09-07 WO PCT/US2016/050559 patent/WO2017044491A1/en not_active Ceased
- 2016-09-07 IL IL290994A patent/IL290994B2/en unknown
- 2016-09-07 CN CN201680065080.6A patent/CN108348518A/zh active Pending
- 2016-09-07 IL IL303605A patent/IL303605B2/en unknown
- 2016-09-07 EP EP21201628.1A patent/EP3977996B1/en active Active
- 2016-09-07 ES ES21201628T patent/ES2980894T3/es active Active
- 2016-09-07 PL PL21201628.1T patent/PL3977996T3/pl unknown
- 2016-09-07 CA CA2997191A patent/CA2997191C/en active Active
- 2016-09-07 EP EP21170586.8A patent/EP3922249B1/en active Active
- 2016-09-07 DK DK16771034.2T patent/DK3347016T3/da active
- 2016-09-07 EP EP16767114.8A patent/EP3347014B1/en active Active
- 2016-09-07 PL PL21201653.9T patent/PL3964213T3/pl unknown
- 2016-09-07 EP EP24211831.3A patent/EP4491238A3/en active Pending
- 2016-09-07 IL IL316004A patent/IL316004A/en unknown
- 2016-09-07 IL IL319574A patent/IL319574A/en unknown
- 2016-09-07 EP EP24162567.2A patent/EP4410289A1/en not_active Withdrawn
- 2016-09-07 SG SG10202012842SA patent/SG10202012842SA/en unknown
- 2016-09-07 US US15/258,828 patent/US9884057B2/en active Active
- 2016-09-07 IL IL300474A patent/IL300474B2/en unknown
- 2016-09-07 JP JP2018512296A patent/JP7281280B2/ja active Active
- 2016-09-07 US US15/258,977 patent/US11173153B2/en active Active
- 2016-09-07 AU AU2016318775A patent/AU2016318775B2/en active Active
- 2016-09-07 US US15/258,969 patent/US11179378B2/en active Active
- 2016-09-07 EP EP24153857.8A patent/EP4342493A3/en active Pending
- 2016-09-07 ES ES21201653T patent/ES2981632T3/es active Active
- 2016-09-07 EP EP16767115.5A patent/EP3347015B1/en active Active
- 2016-09-07 JP JP2018512235A patent/JP7027308B2/ja active Active
- 2016-09-07 AU AU2016318785A patent/AU2016318785B2/en active Active
- 2016-09-07 PL PL21170586.8T patent/PL3922249T3/pl unknown
- 2016-09-07 AU AU2016318786A patent/AU2016318786B2/en active Active
- 2016-09-07 ES ES21170586T patent/ES2976071T3/es active Active
- 2016-09-07 WO PCT/US2016/050581 patent/WO2017044503A1/en not_active Ceased
- 2016-09-07 ES ES16767115T patent/ES2898932T3/es active Active
- 2016-09-07 EP EP16767112.2A patent/EP3347013B1/en active Active
- 2016-09-07 CA CA2997187A patent/CA2997187C/en active Active
- 2016-09-07 ES ES16767112T patent/ES2909329T3/es active Active
- 2016-09-07 CN CN202310713998.9A patent/CN116919962A/zh active Pending
- 2016-09-07 JP JP2018512234A patent/JP7152306B2/ja active Active
- 2016-09-07 JP JP2018512253A patent/JP7281279B2/ja active Active
- 2016-09-07 WO PCT/US2016/050580 patent/WO2017044502A1/en not_active Ceased
- 2016-09-07 EP EP24162566.4A patent/EP4410288B1/en active Active
- 2016-09-07 AU AU2016318780A patent/AU2016318780B2/en active Active
- 2016-09-07 IL IL290985A patent/IL290985B2/en unknown
- 2016-09-07 CA CA3288371A patent/CA3288371A1/en active Pending
- 2016-09-07 EP EP21201653.9A patent/EP3964213B1/en active Active
- 2016-09-07 CN CN201680065020.4A patent/CN108348517B/zh active Active
- 2016-09-07 IL IL290993A patent/IL290993B2/en unknown
- 2016-09-07 CN CN201680065041.6A patent/CN108495630A/zh active Pending
- 2016-09-07 DK DK16767112.2T patent/DK3347013T3/da active
- 2016-09-07 DK DK16767114.8T patent/DK3347014T3/da active
-
2017
- 2017-12-21 US US15/850,307 patent/US10869861B2/en active Active
-
2018
- 2018-02-26 IL IL257744A patent/IL257744B/en unknown
- 2018-02-26 IL IL257747A patent/IL257747B/en unknown
- 2018-02-26 IL IL257746A patent/IL257746B/en unknown
- 2018-02-28 IL IL257785A patent/IL257785B/en unknown
-
2020
- 2020-03-04 US US16/809,045 patent/US11298347B2/en active Active
- 2020-12-17 US US17/125,164 patent/US12121514B2/en active Active
-
2021
- 2021-10-27 US US17/511,795 patent/US11806340B2/en active Active
- 2021-10-28 US US17/512,827 patent/US11806341B2/en active Active
-
2022
- 2022-02-16 JP JP2022022123A patent/JP2022078104A/ja active Pending
- 2022-02-28 IL IL290992A patent/IL290992B2/en unknown
- 2022-04-06 US US17/714,276 patent/US20220296582A1/en not_active Abandoned
- 2022-05-05 AU AU2022203039A patent/AU2022203039B2/en active Active
- 2022-06-20 AU AU2022204324A patent/AU2022204324B2/en active Active
- 2022-06-21 AU AU2022204355A patent/AU2022204355B2/en active Active
- 2022-07-11 AU AU2022205142A patent/AU2022205142B2/en active Active
- 2022-09-29 JP JP2022155714A patent/JP7532465B2/ja active Active
- 2022-12-09 JP JP2022197128A patent/JP2023036671A/ja not_active Withdrawn
- 2022-12-09 JP JP2022197117A patent/JP2023051937A/ja not_active Withdrawn
-
2023
- 2023-10-30 US US18/497,338 patent/US20240100036A1/en active Pending
- 2023-10-30 US US18/497,386 patent/US20240075022A1/en active Pending
-
2024
- 2024-07-31 JP JP2024125021A patent/JP2024164036A/ja active Pending
- 2024-09-18 US US18/888,877 patent/US20250120962A1/en active Pending
- 2024-10-23 US US18/924,522 patent/US20250127771A1/en active Pending
- 2024-11-11 AU AU2024259882A patent/AU2024259882A1/en active Pending
- 2024-11-11 AU AU2024259877A patent/AU2024259877A1/en active Pending
-
2025
- 2025-08-07 JP JP2025131955A patent/JP2025179063A/ja active Pending
- 2025-08-07 JP JP2025131952A patent/JP2025183206A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3256579T3 (en) | Cysteinprotease | |
| PL3977996T3 (pl) | Leczenie zespołu tourette’a | |
| IL249600A0 (en) | Bone marrow cell transplant treatment | |
| DK3250592T3 (en) | Anti-transthyretin-antistoffer | |
| IL249454B (en) | Treatment of lymphomas | |
| IL254393A0 (en) | Methods for treating diseases associated with pathological changes in protein | |
| GB201502137D0 (en) | Treatment | |
| GB201522243D0 (en) | Treatment | |
| GB201519450D0 (en) | Novel treatment | |
| AU361999S (en) | Ballustrade | |
| DK3133099T3 (en) | Polymermodificeret polyoldispersion | |
| GB201508841D0 (en) | Treatment | |
| GB201402909D0 (en) | Treating infection | |
| PT3370756T (pt) | Combinação de canrenoato e exenatido | |
| DK3250312T3 (en) | Urea-metalnitrat-scr-system | |
| DK3242882T3 (en) | Cgrp-antagonistpeptider | |
| GB201503008D0 (en) | Treatment | |
| PL3287339T3 (pl) | Powóz | |
| GB201519573D0 (en) | Combination | |
| GB2536575B (en) | Oven | |
| GB201518349D0 (en) | Treatment | |
| GB201515739D0 (en) | Treatment | |
| GB201514008D0 (en) | Treatment | |
| GB2555225B (en) | Hydrocarbon-contamination treatment unit | |
| AU5516P (en) | LEP08 Lepidosperma squamatum |